The FDA granted Fast Track Designation for RAD101, following company announcements made on July 29, 2025, from Sydney.
2 reports, 2 independent
Updated 00:00
Still developing
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Fast Track Designation for RAD101, following company announcements made on July 29, 2025, from Sydney.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Partnership provides clinical supply and Phase 3 trial design alignment for RAD101.1 source
FDA grants Fast Track Designation for RAD101 after company announcements from Sydney.1 source
Keep exploring
The entities involved
-
FDA
- Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.
- Hemogenyx Pharmaceuticals Plc submitted an IND application for its HG-CT-1 therapy with the FDA and is building infrastructure for early commercialization in Europe.
-
Sydney
capital city of New South Wales, Australia
Coverage
Newest first; wire copies grouped- manilatimes.net
- GlobeNewswireRadiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to es